Avalo Therapeutics (AVTX) Expected to Post Quarterly Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Avalo Therapeutics to announce earnings of ($0.66) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, analysts expect Avalo Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Avalo Therapeutics Trading Down 2.6%

AVTX opened at $19.01 on Thursday. Avalo Therapeutics has a 1-year low of $6.51 and a 1-year high of $24.27. The company has a market capitalization of $1.01 billion, a PE ratio of -3.48 and a beta of 0.78. The firm’s 50 day simple moving average is $16.93 and its two-hundred day simple moving average is $16.17.

Insider Activity at Avalo Therapeutics

In related news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares in the company, valued at approximately $931,968. This represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 77,513 shares of company stock worth $1,560,121. Company insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd grew its position in shares of Avalo Therapeutics by 190.0% during the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after purchasing an additional 26,508 shares in the last quarter. Squadron Capital Management LLC bought a new stake in Avalo Therapeutics in the fourth quarter worth $2,361,000. SummitTX Capital L.P. purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $3,557,000. Millennium Management LLC raised its position in Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after purchasing an additional 522,548 shares during the period. Finally, Caligan Partners LP raised its holdings in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after buying an additional 48,200 shares during the period. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AVTX. BTIG Research reissued a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Weiss Ratings lowered Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Piper Sandler restated an “overweight” rating and issued a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Finally, Mizuho raised their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Thirteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Avalo Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $45.80.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.